Elevance Health, Inc. (ELV)
Elevance Health: Buy A Dividend Growth Machine
Elevance Health, Inc. has shown remarkable dividend growth in the past decade, exceeding revenue and EPS expectations for the first quarter. Elevance's balance sheet remains A-rated, and shares of the stock could be undervalued by 14%. The company is positioned to generate over 30% cumulative total returns through 2026, making it a high-quality investment option.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
Elevance Health, Inc. (ELV) Q2 2024 Earnings Call Transcript
Elevance Health, Inc. (NYSE:ELV ) Q2 2024 Earnings Call Transcript July 17, 2024 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO Mark Kaye - CFO Felicia Norwood - President, Government Health Benefits Pete Haytaian - President, Carelon Morgan Kendrick - President, Commercial Health Benefits Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Lance Wilkes - Bernstein Kevin Fischbeck - Bank of America Josh Raskin - Nephron Research Lisa Gill - JPMorgan Justin Lake - Wolfe Research Erin Wright - Morgan Stanley Michael Ha - Baird Andrew Mok - Barclays Ryan Langston - Cowen Stephen Baxter - Wells Fargo Scott Fidel - Stephens Sarah James - Cantor Fitzgerald George Hill - Deutsche Bank Whit Mayo - Leerink Partners Dave Windley - Jefferies Ann Hynes - Mizuho Securities Ben Hendrix - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Second Quarter Earnings Conference Call.
Elevance Stock Slides Despite Earnings Beat as Medicaid Membership Declines
Elevance Health (ELV) topped analyst expectations with its second-quarter results, but shares of the health insurance provider fell in intraday trading Wednesday amid declining Medicaid membership.
Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates
Elevance Health (ELV) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.99 per share. This compares to earnings of $9.04 per share a year ago.
Here's Why Elevance Health (ELV) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q2 Earnings
Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
